Aim: Current evidence relating testosterone to cardiovascular disease and mortality is inconclusive. Cellular effects of testosterone are mediated by androgen receptor and longer receptor gene CAG repeat length correlates with reduced transcriptional activity. We investigated the independent and interactive association of total testosterone and CAG repeat length with incident cardiovascular disease (CVD), chronic kidney disease (CKD) and mortality in Chinese men with type 2 diabetes. Results: In this cohort (mean age: 58.6 years, disease duration: 15.4 years), CAG repeat number ranged from 11 to 32 with median of 23, and 9.3% had low testosterone. Over follow-up of 5.8 years, 49 (10.3%) men had CVD, 139 (29.3%) had CKD, and 43 (9.1%) died. In multivariate Cox regression adjusted for age, duration of diabetes, and cardiometabolic risk factors, both total testosterone and interaction term of total testosterone × CAG repeat were associated with all-cause death with respective hazard ratios 1.63 (P = 0.002) and 0.98 (P = 0.004). Total testosterone and CAG repeat were not related to incident CVD or CKD.
increased death in men with high compared with low testosterone. 10, 11 Heterogeneity in risk profile of the study cohort, methods of hormonal measurements, endpoint ascertainment, and other statistical consideration such as adjustment of explanatory variables might contribute to these mixed results. Adding to the ambiguity about the long-term health impact of low testosterone, recently published retrospective cohort studies and meta-analyses of randomized controlled trials on testosterone replacement in men with low testosterone suggest that testosterone treatment might increase cardiovascular disease (CVD) and mortality, [12] [13] [14] despite improvements on body composition, blood pressures, and blood glucose. 15, 16 Downstream action of testosterone requires binding of testosterone or its metabolites to androgen receptors at target tissues. Exon 1 of the androgen receptor gene located on the X chromosome (Xq11 .2 to Xq12) contains stretches of CAG repeats which encodes a polyglutamate tract of the N-terminal of the receptor. 17 The length of CAG repeats has been shown to have functional significance with longer length denoting reduced receptor transcription activity and thus diminished androgen sensitivity. 17 The relationship between CAG repeat length and metabolic phenotypes was previously investigated with varying results. In some studies, long CAG repeat length was found to correlate with adverse metabolic changes including increased adiposity, triglyceride, and blood pressure, 18, 19 but in others, protective changes such as low blood glucose and elevated high density-lipoprotein (HDL) cholesterol were reported. 20, 21 The current literature relating testosterone to cardiovascular outcomes is equivocal, and existing recommendations on testosterone replacement lack support from robust evidence on the benefit and safety of testosterone, which is still widely prescribed as an anti-ageing solution to older men. We hypothesised that the risk association of testosterone levels with cardiovascular events may be altered by other biological determinants such as androgen receptor activity that modify downstream androgenic effects. In the present study, we examined the independent association of total testosterone and CAG repeat length polymorphism of androgen receptor gene with incident CVD, chronic kidney disease (CKD), and all-cause mortality in a prospective cohort of Chinese men with type 2 diabetes. We further tested whether CAG repeat length has modulatory effects on the relationship between testosterone and outcome. Blood samples were stored at −20°C prior to extraction of DNA. DNA was isolated from peripheral leukocytes using phenol extraction. The DNA fragments containing the CAG trinucleotide repeats were amplified by polymerase chain reaction using primers that flanked the region (forward primer 5′-GCCTGTTGAACTCTTCTGAGC-3″ and reverse primer 5′-CGATGGGCTTGGGGAGAACCATCCTCA-3″). The amplified fragment was sequenced using a nested primer (5′-TGGAAG ATTCAGCCAAGCTC-3′) and was analysed by the Applied Biosystem 3730x/DNA Analyser (Thermofisher Scientific). The number of CAG repeat in each sample report was manually counted.
| Outcome identification and definition
The Hospital Authority (HA) is a statutory body which governs all public hospitals and out-patient clinics and provides 95% of the total hospital bed-days in Hong Kong. 22 Diagnosis codes listed as principal diagnosis on discharge summaries were used to identify clinical outcome for this study. Coronary heart disease was defined as myocardial infarction (ICD-9 code 410), ischaemic heart disease (ICD-9 code 411-414), or death owing to coronary heart disease (ICD-9 code 410-414). Congestive heart failure was defined as nonfatal or fatal heart failure (ICD-9 code 428). Stroke 1.233 is the adjusting coefficient for Chinese. 23 Chronic kidney disease was defined as eGFR <60 mL/min/1.73m 2 .
| Statistical analysis
Statistical analysis was performed using the Statistical Package for 24 Only patients without history of CVD or CKD were included in the analysis of the incidence of the respective event. All statistical analyses tests were two-tailed with statistically significance defined at P < 0.05.
| RESULTS
In this cohort of 474 men with type 2 diabetes (mean age 58.6 ± 12.1 years, mean disease duration 15.4 ± 7.3 years), 42 (9.3%) had low testosterone. CAG repeat length of androgen receptor gene was normally distributed with a range of 11 to 32 and a median of 23 ( Figure 1 ).
At baseline, men with low testosterone had greater BMI and waist circumference, higher triglyceride levels but lower LDL-cholesterol and HDL-cholesterol compared with men without low testosterone ( Figure 2 . High total testosterone was associated with increased mortality when CAG repeat length was the shortest, but with decreased mortality when CAG repeat length was the longest. In patients with CAG repeats within the IQR of 21 to 25, total testosterone was not related to all-cause mortality. Neither total testosterone nor CAG repeat length were associated with incident CVD and CKD in the Cox models.
| DISCUSSION
In this longitudinal cohort of middle-aged men with type 2 diabetes, we found that high total testosterone was associated with increased all-cause mortality in the presence of short CAG repeats but conferred protection when CAG repeat length was long. Our results indicated modulatory effects of CAG repeat length on the relation between testosterone and mortality. We did not detect an association of total testosterone or CAG repeat length with either cardiovascular or renal events.
Men with low testosterone have a more adverse metabolic profile compared with counterparts with normal testosterone. In the present study, for comparable age and disease duration, men with low testosterone were significantly more obese, had higher LDL-cholesterol, triglyceride, and urine albuminuria but lower HDL-cholesterol, although blood pressures and glycemic measures were similar. On the other hand, metabolic attributes did not differ between men with CAG repeat length above and below the median. Previous small cross-sectional studies have reported variable changes to metabolic risk factors in relation to CAG repeat length. [18] [19] [20] [21] More recently, however, two large European longitudinal studies of community-dwelling men reported no correlation between CAG repeat length and metabolic indicators. 25, 26 One explanation for the absence of clear genotypephenotype association is that testosterone has actions that are mediated through pathways not involving androgen receptors, for instance, via conversion to non-androgenic metabolites such as estradiol. 27 It is also possible that the effects of CAG repeat length are altered by testosterone availability. In one study of 675 Filipino men, CAG repeat length had opposing influence on androgen-sensitive traits according to testosterone levels. Among men with low testosterone, lengthening of CAG was linked to reduced muscle mass and strength, whereas in men with high testosterone, androgen-sensitive traits were enhanced by longer CAG repeats. 28 Lastly, treatment with glucose lowering drugs, blood pressure lowering drugs and statins might have confounded the relationship between CAG repeat length polymorphism and clinical variables.
The relationship between circulating testosterone and CVD or mortality has been extensively investigated in men with or without diabetes. Most studies indicated higher risks of CVD or mortality in men with low testosterone. [7] [8] [9] In a meta-analysis of 12 studies comprising 17 091 men of mean age of 61 years followed up for 9.7 years, per 2.18-SD decrease of total testosterone was associated with 35%
and 25% increased hazard of all-cause and cardiovascular mortality, respectively. 9 More recently, the Health in Men Study, which recruited 3637 older men of mean age 77 years, similarly showed higher rates of cardiovascular and all-cause mortality in those with low compared with normal levels of free testosterone over a 5-year observation period. 29 In contrast, 15-year follow-up of the Massachusetts Male Ageing Study cohort consisting of 1686 middle-aged men whose mean age was 55 years found reduced mortality from coronary heart disease in men with low free testosterone, such that the relative risk of an outcome was decreased by 20% for every 1-SD reduction in testosterone level. 10 Among 788 men with type 2 diabetes of mean age 66 years from the Fremantle Diabetes Study followed for 4 years, risk of death from any cause was 78% higher in those with total testosterone at the top quintile (>16.9 nmol/L) than bottom quintile (≤8.6 nmol/L). 11 The results from the present study suggest that relations between total testosterone and mortality are influenced by CAG repeat length. We observed an increase in the hazard of all-cause mortality with high total testosterone when CAG repeat length was short.
Conversely, high total testosterone was associated with lowered mortality when CAG repeat length was long. In a previous case-control study of 544 men, CAG repeat length was not linked to coronary heart disease or myocardial infarction, 30 although from another smaller study of 131 men who were evaluated with coronary angiography, short CAG repeat was suggested to predispose to more severe arterial stenosis. 31 To our knowledge, prior studies have not specifically investigated the interactive effects of testosterone and CAG repeat length polymorphism on major clinical outcomes, and these findings call for validation in larger cohorts.
Testosterone replacement has been reported by several researchers to increase incidence of cardiovascular events, 12, 13, 32 despite improvements in metabolic indicators in short to intermediate term clinical studies, 15, 16 raising uncertainties about the benefit to risk ratio of treating men with less overt hypogonadism such as those with low testosterone secondary to ageing or diabetes. The Testosterone in
Older Men study which investigated the effects of testosterone gel in 209 older men with multiple comorbidities observed an excess of cardiovascular events in the active arm, although the study was not powered to test this outcome. 32 In a meta-analysis comprising 2994 men from 27 randomized controlled studies which have reported on more pronounced in older men with pre-existing atherosclerotic disease. 13 Our study adds to current insights regarding the safety of testosterone replacement and suggest that CAG repeat length may be an important risk determinant. Shorter CAG repeat length, which confers greater transcriptional activity of the androgen receptor, accentuated the rise in mortality risk in connection with high total testosterone.
On the other hand, high testosterone was protective in the presence of long CAG repeat length. Our findings therefore support an interactive effect of CAG repeat length and testosterone on mortality risk.
Mortality risk seems low with testosterone replacement in men with long CAG repeats but not in those with short CAG repeats.
We acknowledge the following limitations in our study. First, total testosterone but not free or bioavailable testosterone was measured.
Since total testosterone levels are affected by SHBG which in turn is sensitive to alteration in physiological conditions, regression models were adjusted for relevant variables including age and BMI to minimize confounding. Second, immunoassay instead of mass spectrometry was used for testosterone measurement. Whilst immunoassay may be less accurate in determining hormonal levels in specimens that contain very low concentrations such as testosterone in children and women, measurements in samples from men containing higher levels have shown reasonable accuracy. Third, we did not adjust for the collection time of blood sample used for testosterone measurement. As testosterone levels vary during the course of the day, inconsistency in sample collection time may affect the results. However, since all patients were instructed to attend the Centre in the morning and samples were routinely obtained between 0800 and 0900 hours, the narrow time frame of blood collection should minimize confounding due to intra-day hormonal variation. Fourth, the small sample size might have limited the power of the study to clarify the association between total testosterone, CAG repeat length, and outcomes. Fifth, we recognize the potential sampling bias in this study. Only men with diabetes were included, and results are not generalisable to men without diabetes.
In conclusion, we demonstrated that CAG repeat length modifies the association between total testosterone and all-cause mortality in men with type 2 diabetes. Our results suggest that CAG repeat length may prove useful in risk stratification of men for testosterone replacement and, in particular, identification of men who may be more sensitive to the harmful effects of testosterone.
FIGURE 2
Graph to show the relations between total testosterone level and linear predictor stratified by different CAG repeat length on all-cause mortality
